The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and uncertain evidence that it helps patients.
https://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.png00https://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.png2022-04-06 08:00:552022-04-06 08:00:55Inside a Campaign to Get Medicare Coverage for a New Alzheimer’s Drug
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.